Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Kristin Schmiedeberg, Nicolas Vuilleumier, Sabrina Pagano, Werner C Albrich, Burkhard Ludewig, Johannes von Kempis, Andrea Rubbert-Roth
Topics & Concepts
MedicineRheumatoid arthritisVaccinationSeroconversionImmunologySerologyInternal medicineImmunogenicityAntibodyImmune systemTolerabilityClinical trialImmunosuppressionScopusMEDLINESARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesT-cell and B-cell Immunology